SecBot SecBot

REPL

Replimune Group, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001737953 Biotech & Drug Discovery
$21.41 −0.48 (−2.19%)
Nov 16 4:00 PM ET · prev $21.89
Market cap
$2.1B
Mid cap
Consensus
Buy
87% Buy or better · 15 analysts
Median target
🔒 Subscribers only
1 year
+144.1%
from $8.77 · Nov 17
30 days
+93.8%
from $11.05
52-week range
$1.70–23.28
−8% from high · low Apr 13
Avg volume 20D
3.44M
shares / day
Short interest
24.61M
≈26.0% of shares · +6.2%
Days to cover
8.3
at average volume
Insider net
+$30.8M
1 buyer · 8 sellers · 12 mo
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
29
analyzed by SecBot
SecBot read MIXED 15 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 13 neutral oldest → newest, height = score
Avg score ·High conf. 10/15

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $33.0M at an average $12.06. 8 insiders sold $2.2M. Price is 78% above their cost.

  • InstitutionsBULLISH

    Q3 2026: 30 added (2 new), 19 trimmed or exited. Largest new: Marshall Wace $50.5M.

  • AnalystsBULLISH

    13 of 15 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +6.2% to 24.61M shares. 8.3 days to cover, ≈26.0% of shares.

  • TrendUPTREND

    44% above its 50-day average. New closing high $23.28 on Nov 10.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 24.

Who's buying

13F· Q3 2026
2
new positions
0
exits
$50.5M
in new stakes · top 1 shown
FundMoveSharesValue
MARSHALL WACE, LLPNEW3,815,373$50.5M
Artisan Partners Limited PartnershipDOUBLED2,213,328$29.3M
MORGAN STANLEYDOUBLED2,137,865$28.3M
Nuveen, LLCDOUBLED1,360,211$18.0M
VANGUARD PORTFOLIO MANAGEMENT LLCADD853,651$11.3M
JANE STREET GROUP, LLCTRIM761,835$10.1M
FMR LLCTRIM609,168$8.1M
BARCLAYS PLCADD332,977$4.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 87% rate it Buy or better
Strong Buy6Buy7Hold1Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Oct 29, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Aug 26, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 7, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 7, 2026Wedbush
UPGRADE
UPGRADEOutperform
Aug 4, 2026Leerink Partners
UPGRADE
UPGRADEOutperform

Insider ledger

Form 4
$33.0M
bought · 1 insider
$2.2M
sold · 8 insiders
+77.5%
vs their $12.06 cost
DateInsiderTypeValue
Nov 9, 2026
SLATTERY JOSEPH P
Director
Nov 9, 2026
SELL$113.4K
Nov 2, 2026
Dhingra Kapil
Director
Nov 2, 2026
SELL$408.5K
Nov 2, 2026
Dhingra Kapil
Director
Nov 2, 2026
EXERCISE$75.5K
Aug 20, 2026
Astley-Sparke Philip
Director
Aug 20, 2026
GIFT50,000 sh
Aug 17, 2026
Hill Emily Luisa
Chief Financial Officer
Aug 17, 2026
SELL$132.2K
Aug 11, 2026
BAKER BROS. ADVISORS LP
Director
Aug 11, 2026
BUY$1.5M
Aug 11, 2026
BAKER BROS. ADVISORS LP
Director
Aug 11, 2026
BUY$31.5M
Aug 10, 2026
Xynos Konstantinos
Chief Medical Officer
Aug 10, 2026
SELL$148.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
24,609,876
shares short
+6.2%
vs prior settlement
8.3
days to cover
≈26.0%
of shares outstanding
Trading halts
Jul 30, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 10, 2026 SEC
Two Replimune directors sold a total of $522K in open-market sales over a week, with Kapil Dhingra selling $409K at…
CLUSTER · Impact 2/10
Nov 10, 2026 SEC
State Street Corp filed a Schedule 13G disclosing a 4.4% passive stake in Replimune Group as of September 30, 2026…
SC 13G · Impact 3/10
Nov 9, 2026 Insider
SLATTERY JOSEPH P sold 5,200 shares
Director @ $21.80 ($113.4K)
Nov 4, 2026 Earnings calendar
REPL Q2 2027 Earnings Scheduled · 2026-11-04
Nov 2, 2026 Insider
Dhingra Kapil sold 21,500 shares
Director @ $19.00 ($408.5K)
Nov 2, 2026 Insider
Dhingra Kapil acquired via exercise 43,169 shares
Director @ $1.75 ($75.5K)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · NEW
3,815,373 shares ($50.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 4, 2026
Earnings date
REPL Q2 2027 Earnings Scheduled · 2026-11-04
Oct 28, 2026
Earnings
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
TUDRIQEV first delivered to patients for advanced melanoma on October 6th
Oct 22, 2026
Earnings
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the...
Oct 1, 2026
Press release
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S…
Sep 18, 2026
M&A
REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses
SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all…

SecBot reports

29 filings · 3 press releases · 8 bullish · 5 bearish · 2 mixed · 14 neutral
All REPL filing & press-release reports (32)